---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-033592"
form_type: "8-K"
ticker: "RZLT"
cik: "0001509261"
company_name: "Rezolute, Inc."
filed_at: "2026-03-24T23:59:59+00:00"
generated_at: "2026-05-15T09:11:49.606676+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Rezolute provides FDA meeting update after Phase 3 HI trial missed primary endpoint

## Summary
- sunRIZE Phase 3 ersodetug trial missed primary endpoint (SMBG hypoglycemia reduction); FDA acknowledged behavioral confounders.
- FDA encouraged submission of study reports and analysis datasets for independent evaluation; company expects update in H2 2026.
- Preliminary open-label extension data show continued glycemic improvement and reduction of background therapies.
- Company believes FDA did not dismiss program; outcomes to be presented at upcoming scientific conference.

## SEC filing metadata
- accession: 0001104659-26-033592
- form_type: 8-K
- ticker: RZLT
- cik: 0001509261
- company_name: Rezolute, Inc.
- filed_at: 2026-03-24T23:59:59+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1509261/000110465926033592/0001104659-26-033592-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1509261/000110465926033592/tm269642d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-033592
- JSON: https://secwatch.observer/filing/0001104659-26-033592.json
- Plain text: https://secwatch.observer/filing/0001104659-26-033592.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.